The PTOV1 (Prostate Tumor Overexpressed 1) antibody is a tool used to detect the PTOV1 protein, initially identified as a gene overexpressed in prostate cancer. Discovered in the early 2000s, PTOV1 is implicated in tumor progression, cell proliferation, and transcriptional regulation. It localizes to both the cytoplasm and nucleus, interacting with chromatin-modifying complexes and influencing signaling pathways like PI3K/AKT. Elevated PTOV1 expression correlates with aggressive prostate cancer phenotypes, including metastasis and therapy resistance. Beyond prostate cancer, studies link PTOV1 to other malignancies, such as breast and colorectal cancers, where it may drive oncogenic processes or serve as a prognostic marker. The antibody enables researchers to study PTOV1's expression patterns, subcellular distribution, and functional roles through techniques like immunohistochemistry, Western blotting, and immunofluorescence. Its development has facilitated insights into PTOV1's dual roles in tumorigenesis and normal cellular processes, though mechanistic details remain under investigation. As a potential therapeutic target or diagnostic biomarker, PTOV1 continues to be a focus in cancer research, with its antibody playing a key role in advancing these explorations.